Entrada Therapeutics, Inc.
entradatx.comWhat Do They Do?
Develops genetic medicines for patients with neuromuscular diseases, including Duchenne muscular dystrophy, and inherited retinal diseases.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that…View ↗
Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (“DMD”) in the United Kingdom…View ↗
The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases. Both…View ↗
We are developing therapeutic candidates to address the genetic basis, at the exon-specific level, of DMD. In our neuromuscular disease…View ↗
How Do They Make Money?
Most revenue to date comes from Vertex under its collaboration. Entrada has received an upfront payment and payments for research activities; additional milestone payments depend on specified research, development, regulatory or commercial achievements, and royalties are tied to future product sales.
10-K for FY2025, filed Feb 26, 2026 10-K for FY2022, filed Mar 6, 2023
$25.4M
-
10-K for FY2025, filed Feb 26, 2026
$25.4M ↗
Who Are Their Customers?
Vertex is the collaboration partner from which substantially all revenue to date has come.
10-K for FY2025, filed Feb 26, 2026 10-K for FY2022, filed Mar 6, 2023Substantially all of our revenue to date has been derived from the Vertex Agreement. We do not expect to generate any revenue from the sale…View ↗
The Vertex Agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for…View ↗
Do Revenues Turn Into Profits?
No. It lost $143.8M in FY2025.
10-K for FY2025, filed Feb 26, 2026
−$157.9MView ↗
10-K for FY2025, filed Feb 26, 2026
−$143.8MView ↗
10-K for FY2025, filed Feb 26, 2026
−$129.6MView ↗
How Are They Changing?
Ocular work advances
The earlier report described ocular disease as an area of ongoing discovery; the latest report describes ocular programs in lead optimization and says it selected an ocular clinical candidate.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Feb 26, 2026High unmet need continues to exist across a wide range of ocular diseases including macular dystrophies, photoreceptor diseases, optic…View ↗
The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases. Both…View ↗
Who Do They Compete With?
Competes with PTC Therapeutics, Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Avidity, Wave Life Sciences, Dyne Therapeutics, BioMarin Pharmaceutical, Solid Biosciences, REGENXBIO, AMO Pharma, PepGen, Design Therapeutics, Expansion Therapeutics, Laboratories Théa, Nacuity Pharmaceuticals, and Reforgene
10-K for FY2025, filed Feb 26, 2026Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is…View ↗
Loading...
